- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03952585
De-intensiveret strålebehandling med kemoterapi (cisplatin) eller immunterapi (Nivolumab) til behandling af patienter med tidligt stadie, HPV-positiv, ikke-ryger associeret orofaryngeal cancer
Et randomiseret fase II/III-forsøg med de-intensiveret strålebehandling til patienter med tidligt stadie, P16-positiv, ikke-ryger associeret orofaryngeal cancer
This phase II/III trial studies how well a reduced dose of radiation therapy works with nivolumab compared to cisplatin in treating patients with human papillomavirus (HPV)-positive oropharyngeal cancer that is early in its growth and may not have spread to other parts of the body (early-stage), and is not associated with smoking. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial is being done to see if a reduced dose of radiation therapy and nivolumab works as well as standard dose radiation therapy and cisplatin in treating patients with oropharyngeal cancer.
Studieoversigt
Status
Betingelser
- Orofarynx pladecellekarcinom
- Planocellulært karcinom
- Basaloid planocellulært karcinom
- Klinisk fase I HPV-medieret (p16-positiv) orofarynxcarcinom AJCC v8
- Klinisk fase II HPV-medieret (p16-positiv) orofaryngealt karcinom AJCC v8
- Papillært planocellulært karcinom
- Patologisk stadie I HPV-medieret (p16-positiv) orofaryngealt karcinom AJCC v8
- Patologisk fase II HPV-medieret (p16-positiv) orofaryngealt karcinom AJCC v8
Intervention / Behandling
- Andet: Quality-of-Life Assessment
- Medicin: Cisplatin
- Procedure: Biospecimen Collection
- Procedure: Computed Tomography
- Procedure: Magnetic Resonance Imaging
- Andet: Questionnaire Administration
- Procedure: Positron Emission Tomography
- Biologisk: Nivolumab
- Stråling: Intensity-Modulated Radiation Therapy
- Andet: Fludeoxyglucose F-18
- Procedure: Biopsy Procedure
- Stråling: Image Guided Radiation Therapy
Detaljeret beskrivelse
PRIMARY OBJECTIVES:
I. To demonstrate non-inferiority in terms of progression-free survival (PFS) of concurrent reduced-dose radiation therapy (RT) with cisplatin or concurrent reduced-dose radiation therapy with nivolumab to the current standard of care (standard-dose RT with cisplatin). (Phase II) (Arm 2 [concurrent reduced-dose RT with cisplatin] was dropped after interim futility analysis in phase II.) II. To demonstrate non-inferiority in terms of progression-free survival (PFS) of concurrent reduced-dose radiation therapy (RT) with nivolumab to the current standard of care (standard-dose RT with cisplatin). (Phase II) III. To demonstrate co-primary endpoints of non-inferiority of PFS and superiority of quality of life (QOL) as measured by the MD Anderson Dysphagia Inventory (MDADI) of concurrent reduced-dose radiation with cisplatin or concurrent reduced-dose radiation with nivolumab to the current standard of care (standard-dose RT with cisplatin). (Phase III) (Arm 2 [concurrent reduced-dose RT with cisplatin] was dropped after interim futility analysis in phase II.) IV. To demonstrate co-primary endpoints of non-inferiority of PFS and superiority of quality of life (QOL) as measured by the MD Anderson Dysphagia Inventory [MDADI] of concurrent reduced-dose radiation with nivolumab to the current standard of care (standard-dose RT with cisplatin). (Phase III)
SECONDARY OBJECTIVES:
I. To compare patterns of failure (local and regional relapse versus distant) and overall survival between the experimental arm and the control arm.
II. To assess long term PFS, overall survival, and toxicity between the experimental arm and the control arm.
III. To determine acute and late toxicity profiles as measured by the Common Terminology Criteria for Adverse Events (CTCAE).
IV. To explore the symptomatic adverse events (AEs) for tolerability of each treatment arm as measured by the Patient-Reported Outcomes (PRO)-CTCAE.
V. To compare changes in patient-reported outcomes (Hearing Handicap Inventory for Adults-Screening [HHIA-S], European Organization for Research and Treatment of Cancer [EORTC]-Quality of Life Questionnaire [QLQ]30) between the experimental arm and the control arm.
VI. To assess the association of fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/computed tomography (CT) at baseline with locoregional control and PFS.
VII. To estimate the negative predictive value of the 12-14 weeks post-radiation therapy (RT) FDG-PET/CT in terms of locoregional control rates and PFS rates at 1 and 2 years.
EXPLORATORY OBJECTIVES:
I. To collect blood and tissue specimens for future translation research. II. To optimize radiotherapy treatment plan quality assurance methodology for radiotherapy planning and imaging.
III. To compare changes in patient-reported outcomes (European Quality of Life Five Dimension Five Level Scale [EQ-5D-5L]) between the experimental arm and the control arm.
IV. To collect Modified Barium Swallow (MBS) data for future review and analysis.
OUTLINE:
PHASE II: Patients are randomized to 1 of 3 arms.
ARM I: Patients undergo standard dose RT as 70 Gy intensity modulated radiation therapy (IMRT) or image-guided radiation therapy (IGRT) over 6 fractions per week and receive 100 mg/m^2/day cisplatin intravenously (IV) over 30-60 minutes on days 1 and 22. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive fludeoxyglucose F-18 (FDG) and undergo positron emission tomography (PET)/computed tomography (CT) or CT during screening and during follow up, and undergo magnetic resonance imaging (MRI) during follow up. Patients may also undergo tissue biopsy and blood sample collection throughout the study.
ARM II (CLOSED TO ACCRUAL 03-FEB-2023): Patients undergo reduced dose RT as 60 Gy IMRT or IGRT once daily (QD) over 5 fractions per week and receive 100 mg/m^2/day cisplatin IV over 30-60 minutes on days 1 and 22. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive FDG and undergo PET/CT or CT during screening and during follow up, and undergo MRI during follow up. Patients may also undergo tissue biopsy and blood sample collection throughout the study.
ARM III: Beginning 1 week prior to radiation, patients receive 240 mg fixed dose nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks (14 days) for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo reduced dose RT as 60 Gy IMRT or IGRT over 6 fractions per week for 5 weeks in the absence of disease progression or unacceptable toxicity. Patients receive FDG and undergo PET/CT or CT during screening and during follow up, and undergo MRI during follow up. Patients may also undergo tissue biopsy and blood sample collection throughout the study.
PHASE III: Patients are randomized to Arm I and/or Arm III.
After completion of study treatment, patients are followed up at 12-14 weeks, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Arizona
-
Gilbert, Arizona, Forenede Stater, 85234
- Banner MD Anderson Cancer Center
-
Tucson, Arizona, Forenede Stater, 85719
- Banner University Medical Center - Tucson
-
Tucson, Arizona, Forenede Stater, 85719
- University of Arizona Cancer Center-North Campus
-
-
California
-
Antioch, California, Forenede Stater, 94531
- Kaiser Permanente-Deer Valley Medical Center
-
Arroyo Grande, California, Forenede Stater, 93420
- PCR Oncology
-
Auburn, California, Forenede Stater, 95602
- Sutter Auburn Faith Hospital
-
Auburn, California, Forenede Stater, 95603
- Sutter Cancer Centers Radiation Oncology Services-Auburn
-
Bakersfield, California, Forenede Stater, 93301
- AIS Cancer Center at San Joaquin Community Hospital
-
Beverly Hills, California, Forenede Stater, 90211
- Tower Cancer Research Foundation
-
Cameron Park, California, Forenede Stater, 95682
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park
-
Duarte, California, Forenede Stater, 91010
- City of Hope Comprehensive Cancer Center
-
Dublin, California, Forenede Stater, 94568
- Kaiser Permanente Dublin
-
Encinitas, California, Forenede Stater, 92024
- UC San Diego Health System - Encinitas
-
Fremont, California, Forenede Stater, 94538
- Kaiser Permanente-Fremont
-
Fresno, California, Forenede Stater, 93720
- Kaiser Permanente-Fresno
-
Fresno, California, Forenede Stater, 93720
- Fresno Cancer Center
-
Irvine, California, Forenede Stater, 92618
- City of Hope at Irvine Lennar
-
La Jolla, California, Forenede Stater, 92093
- UC San Diego Moores Cancer Center
-
Lancaster, California, Forenede Stater, 93534
- City of Hope Antelope Valley
-
Los Angeles, California, Forenede Stater, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Forenede Stater, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Forenede Stater, 90033
- Los Angeles General Medical Center
-
Marysville, California, Forenede Stater, 95901
- Fremont - Rideout Cancer Center
-
Modesto, California, Forenede Stater, 95356
- Kaiser Permanente-Modesto
-
Mountain View, California, Forenede Stater, 94040
- Palo Alto Medical Foundation-Camino Division
-
Oakland, California, Forenede Stater, 94611
- Kaiser Permanente-Oakland
-
Oakland, California, Forenede Stater, 94611
- Kaiser Permanente Oakland-Broadway
-
Palo Alto, California, Forenede Stater, 94304
- Stanford Cancer Institute Palo Alto
-
Palo Alto, California, Forenede Stater, 94301
- Palo Alto Medical Foundation Health Care
-
Rancho Cordova, California, Forenede Stater, 95670
- Kaiser Permanente-Rancho Cordova Cancer Center
-
Redwood City, California, Forenede Stater, 94063
- Kaiser Permanente- Marshall Medical Offices
-
Richmond, California, Forenede Stater, 94801
- Kaiser Permanente-Richmond
-
Rohnert Park, California, Forenede Stater, 94928
- Rohnert Park Cancer Center
-
Roseville, California, Forenede Stater, 95678
- The Permanente Medical Group-Roseville Radiation Oncology
-
Roseville, California, Forenede Stater, 95661
- Kaiser Permanente-Roseville
-
Roseville, California, Forenede Stater, 95661
- Sutter Cancer Centers Radiation Oncology Services-Roseville
-
Roseville, California, Forenede Stater, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Forenede Stater, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Forenede Stater, 95817
- University of California Davis Comprehensive Cancer Center
-
Sacramento, California, Forenede Stater, 95814
- Kaiser Permanente Downtown Commons
-
Sacramento, California, Forenede Stater, 95823
- Kaiser Permanente-South Sacramento
-
Sacramento, California, Forenede Stater, 95823
- South Sacramento Cancer Center
-
San Diego, California, Forenede Stater, 92134
- Naval Medical Center -San Diego
-
San Diego, California, Forenede Stater, 92103
- UC San Diego Medical Center - Hillcrest
-
San Francisco, California, Forenede Stater, 94115
- Kaiser Permanente-San Francisco
-
San Francisco, California, Forenede Stater, 94158
- UCSF Medical Center-Mission Bay
-
San Jose, California, Forenede Stater, 95119
- Kaiser Permanente-Santa Teresa-San Jose
-
San Jose, California, Forenede Stater, 95124
- Stanford Cancer Center South Bay
-
San Leandro, California, Forenede Stater, 94577
- Kaiser Permanente San Leandro
-
San Luis Obispo, California, Forenede Stater, 93401
- Pacific Central Coast Health Center-San Luis Obispo
-
San Rafael, California, Forenede Stater, 94903
- Kaiser San Rafael-Gallinas
-
Santa Clara, California, Forenede Stater, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
Santa Rosa, California, Forenede Stater, 95403
- Kaiser Permanente-Santa Rosa
-
South Pasadena, California, Forenede Stater, 91030
- City of Hope South Pasadena
-
South San Francisco, California, Forenede Stater, 94080
- Kaiser Permanente Cancer Treatment Center
-
South San Francisco, California, Forenede Stater, 94080
- Kaiser Permanente-South San Francisco
-
Stockton, California, Forenede Stater, 95210
- Kaiser Permanente-Stockton
-
Sunnyvale, California, Forenede Stater, 94086
- Palo Alto Medical Foundation-Sunnyvale
-
Torrance, California, Forenede Stater, 90509
- Torrance Memorial Medical Center
-
Torrance, California, Forenede Stater, 90505
- Torrance Memorial Physician Network - Cancer Care
-
Torrance, California, Forenede Stater, 90503
- City of Hope South Bay
-
Upland, California, Forenede Stater, 91786
- City of Hope Upland
-
Vacaville, California, Forenede Stater, 95688
- Kaiser Permanente Medical Center-Vacaville
-
Vallejo, California, Forenede Stater, 94589
- Kaiser Permanente-Vallejo
-
Walnut Creek, California, Forenede Stater, 94596
- Kaiser Permanente-Walnut Creek
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Rocky Mountain Regional VA Medical Center
-
Aurora, Colorado, Forenede Stater, 80045
- UCHealth University of Colorado Hospital
-
Boulder, Colorado, Forenede Stater, 80304
- Rocky Mountain Cancer Centers-Boulder
-
Colorado Springs, Colorado, Forenede Stater, 80909
- UCHealth Memorial Hospital Central
-
Colorado Springs, Colorado, Forenede Stater, 80907
- Rocky Mountain Cancer Centers-Penrose
-
Colorado Springs, Colorado, Forenede Stater, 80920
- Memorial Hospital North
-
Denver, Colorado, Forenede Stater, 80210
- AdventHealth Porter
-
Fort Collins, Colorado, Forenede Stater, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Forenede Stater, 80528
- Cancer Care and Hematology-Fort Collins
-
Greeley, Colorado, Forenede Stater, 80631
- UCHealth Greeley Hospital
-
Littleton, Colorado, Forenede Stater, 80122
- AdventHealth Littleton
-
Loveland, Colorado, Forenede Stater, 80538
- Medical Center of the Rockies
-
Parker, Colorado, Forenede Stater, 80138
- AdventHealth Parker
-
-
Connecticut
-
Hartford, Connecticut, Forenede Stater, 06102
- Hartford Hospital
-
-
Delaware
-
Newark, Delaware, Forenede Stater, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Forenede Stater, 19713
- Delaware Clinical and Laboratory Physicians PA
-
Newark, Delaware, Forenede Stater, 19713
- Medical Oncology Hematology Consultants PA
-
Newark, Delaware, Forenede Stater, 19718
- Christiana Care Health System-Christiana Hospital
-
-
Florida
-
Coral Gables, Florida, Forenede Stater, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Coral Springs, Florida, Forenede Stater, 33065
- UM Sylvester Comprehensive Cancer Center at Coral Springs
-
Deerfield Beach, Florida, Forenede Stater, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Jupiter, Florida, Forenede Stater, 33458
- Jupiter Medical Center
-
Miami, Florida, Forenede Stater, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Forenede Stater, 33176
- Miami Cancer Institute
-
Miami, Florida, Forenede Stater, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Orlando, Florida, Forenede Stater, 32806
- Orlando Health Cancer Institute
-
Tampa, Florida, Forenede Stater, 33612
- Moffitt Cancer Center
-
Tampa, Florida, Forenede Stater, 33607
- Moffitt Cancer Center-International Plaza
-
Tampa, Florida, Forenede Stater, 33612
- Moffitt Cancer Center - McKinley Campus
-
Wesley Chapel, Florida, Forenede Stater, 33544
- Moffitt Cancer Center at Wesley Chapel
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Forenede Stater, 30303
- Grady Health System
-
-
Hawaii
-
Honolulu, Hawaii, Forenede Stater, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Forenede Stater, 96817
- The Cancer Center of Hawaii-Liliha
-
Honolulu, Hawaii, Forenede Stater, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Forenede Stater, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Forenede Stater, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Forenede Stater, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, Forenede Stater, 96817
- Hawaii Cancer Care Inc-Liliha
-
Honolulu, Hawaii, Forenede Stater, 96817
- Kuakini Medical Center
-
Honolulu, Hawaii, Forenede Stater, 96817
- Queen's Cancer Center - Kuakini
-
Honolulu, Hawaii, Forenede Stater, 96826
- Kapiolani Medical Center for Women and Children
-
Honolulu, Hawaii, Forenede Stater, 96819
- Kaiser Permanente Moanalua Medical Center
-
Lihue, Hawaii, Forenede Stater, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
‘Aiea, Hawaii, Forenede Stater, 96701
- Hawaii Cancer Care - Westridge
-
‘Aiea, Hawaii, Forenede Stater, 96701
- Pali Momi Medical Center
-
-
Idaho
-
Boise, Idaho, Forenede Stater, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Forenede Stater, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Forenede Stater, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Fruitland, Idaho, Forenede Stater, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Forenede Stater, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Forenede Stater, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Forenede Stater, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Forenede Stater, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Aurora, Illinois, Forenede Stater, 60504
- Rush-Copley Medical Center
-
Barrington, Illinois, Forenede Stater, 60010
- Advocate Good Shepherd Hospital
-
Bloomington, Illinois, Forenede Stater, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Forenede Stater, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Forenede Stater, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Forenede Stater, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Forenede Stater, 60611
- Northwestern University
-
Chicago, Illinois, Forenede Stater, 60657
- Advocate Illinois Masonic Medical Center
-
Chicago, Illinois, Forenede Stater, 60612
- Rush MD Anderson Cancer Center
-
Crystal Lake, Illinois, Forenede Stater, 60014
- AMG Crystal Lake - Oncology
-
DeKalb, Illinois, Forenede Stater, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Forenede Stater, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Forenede Stater, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Downers Grove, Illinois, Forenede Stater, 60515
- Advocate Good Samaritan Hospital
-
Effingham, Illinois, Forenede Stater, 62401
- Crossroads Cancer Center
-
Elgin, Illinois, Forenede Stater, 60123
- Advocate Sherman Hospital
-
Eureka, Illinois, Forenede Stater, 61530
- Illinois CancerCare-Eureka
-
Evanston, Illinois, Forenede Stater, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Forenede Stater, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Forenede Stater, 61401
- Illinois CancerCare-Galesburg
-
Geneva, Illinois, Forenede Stater, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Forenede Stater, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, Forenede Stater, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Kewanee, Illinois, Forenede Stater, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Forenede Stater, 61455
- Illinois CancerCare-Macomb
-
Maywood, Illinois, Forenede Stater, 60153
- Loyola University Medical Center
-
O'Fallon, Illinois, Forenede Stater, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Forenede Stater, 61350
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge, Illinois, Forenede Stater, 60068
- Advocate Lutheran General Hospital
-
Pekin, Illinois, Forenede Stater, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Forenede Stater, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Forenede Stater, 61637
- OSF Saint Francis Medical Center
-
Peoria, Illinois, Forenede Stater, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Forenede Stater, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Forenede Stater, 61356
- Illinois CancerCare-Princeton
-
Rockford, Illinois, Forenede Stater, 61114
- UW Health Carbone Cancer Center Rockford
-
Shiloh, Illinois, Forenede Stater, 62269
- Memorial Hospital East
-
Springfield, Illinois, Forenede Stater, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Forenede Stater, 62702
- Springfield Clinic
-
Springfield, Illinois, Forenede Stater, 62781
- Springfield Memorial Hospital
-
Warrenville, Illinois, Forenede Stater, 60555
- Northwestern Medicine Cancer Center Warrenville
-
Washington, Illinois, Forenede Stater, 61571
- Illinois CancerCare - Washington
-
-
Indiana
-
Carmel, Indiana, Forenede Stater, 46032
- IU Health North Hospital
-
Indianapolis, Indiana, Forenede Stater, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Forenede Stater, 46202
- Sidney and Lois Eskenazi Hospital
-
-
Iowa
-
Clive, Iowa, Forenede Stater, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Forenede Stater, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Creston, Iowa, Forenede Stater, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Forenede Stater, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Forenede Stater, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Forenede Stater, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Forenede Stater, 50316
- Iowa Lutheran Hospital
-
Des Moines, Iowa, Forenede Stater, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Forenede Stater, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
West Des Moines, Iowa, Forenede Stater, 50266-7700
- Methodist West Hospital
-
West Des Moines, Iowa, Forenede Stater, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66160
- University of Kansas Cancer Center
-
Lawrence, Kansas, Forenede Stater, 66044
- Lawrence Memorial Hospital
-
Olathe, Kansas, Forenede Stater, 66061
- The University of Kansas Cancer Center - Olathe
-
Overland Park, Kansas, Forenede Stater, 66210
- University of Kansas Cancer Center-Overland Park
-
Salina, Kansas, Forenede Stater, 67401
- Salina Regional Health Center
-
Topeka, Kansas, Forenede Stater, 66606
- University of Kansas Health System Saint Francis Campus
-
Westwood, Kansas, Forenede Stater, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40536
- University of Kentucky/Markey Cancer Center
-
Louisville, Kentucky, Forenede Stater, 40202
- Norton Hospital Pavilion and Medical Campus
-
Louisville, Kentucky, Forenede Stater, 40202
- The James Graham Brown Cancer Center at University of Louisville
-
Louisville, Kentucky, Forenede Stater, 40241
- Norton Brownsboro Hospital and Medical Campus
-
Louisville, Kentucky, Forenede Stater, 40202
- Jewish Hospital
-
-
Louisiana
-
Baton Rouge, Louisiana, Forenede Stater, 70805
- LSU Health Baton Rouge-North Clinic
-
Baton Rouge, Louisiana, Forenede Stater, 70809
- Louisiana Hematology Oncology Associates LLC
-
Baton Rouge, Louisiana, Forenede Stater, 70809
- Mary Bird Perkins Cancer Center
-
Baton Rouge, Louisiana, Forenede Stater, 70808
- Our Lady of the Lake Physician Group
-
Metairie, Louisiana, Forenede Stater, 70006
- East Jefferson General Hospital
-
-
Maine
-
Bath, Maine, Forenede Stater, 04530
- MaineHealth Coastal Cancer Treatment Center
-
Biddeford, Maine, Forenede Stater, 04005
- MaineHealth Maine Medical Center - Biddeford
-
Portland, Maine, Forenede Stater, 04102
- MaineHealth Maine Medical Center - Portland
-
Rockport, Maine, Forenede Stater, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Forenede Stater, 04073
- MaineHealth Cancer Care Center of York County
-
Sanford, Maine, Forenede Stater, 04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
Scarborough, Maine, Forenede Stater, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Forenede Stater, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21204
- Greater Baltimore Medical Center
-
Baltimore, Maryland, Forenede Stater, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bel Air, Maryland, Forenede Stater, 21014
- UM Upper Chesapeake Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Forenede Stater, 02118
- Boston Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Bay City, Michigan, Forenede Stater, 48706
- McLaren Cancer Institute-Bay City
-
Brighton, Michigan, Forenede Stater, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Forenede Stater, 48114
- Trinity Health Medical Center - Brighton
-
Brownstown, Michigan, Forenede Stater, 48183
- Henry Ford Cancer Institute-Downriver
-
Canton, Michigan, Forenede Stater, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Forenede Stater, 48188
- Trinity Health Medical Center - Canton
-
Caro, Michigan, Forenede Stater, 48723
- Caro Cancer Center
-
Chelsea, Michigan, Forenede Stater, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Forenede Stater, 48118
- Chelsea Hospital
-
Clarkston, Michigan, Forenede Stater, 48346
- McLaren Cancer Institute-Clarkston
-
Clinton Township, Michigan, Forenede Stater, 48038
- Henry Ford Macomb Hospital-Clinton Township
-
Dearborn, Michigan, Forenede Stater, 48126
- Henry Ford Medical Center-Fairlane
-
Detroit, Michigan, Forenede Stater, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Forenede Stater, 48201
- Wayne State University/Karmanos Cancer Institute
-
Farmington Hills, Michigan, Forenede Stater, 48334
- Weisberg Cancer Treatment Center
-
Flint, Michigan, Forenede Stater, 48532
- McLaren Cancer Institute-Flint
-
Flint, Michigan, Forenede Stater, 48532
- Singh and Arora Hematology Oncology PC
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Lansing, Michigan, Forenede Stater, 48912
- Mid-Michigan Physicians-Lansing
-
Lansing, Michigan, Forenede Stater, 48910
- Karmanos Cancer Institute at McLaren Greater Lansing
-
Lansing, Michigan, Forenede Stater, 48912
- University of Michigan Health - Sparrow Lansing
-
Lapeer, Michigan, Forenede Stater, 48446
- McLaren Cancer Institute-Lapeer Region
-
Livonia, Michigan, Forenede Stater, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Marlette, Michigan, Forenede Stater, 48453
- Saint Mary's Oncology/Hematology Associates of Marlette
-
Mount Clemens, Michigan, Forenede Stater, 48043
- McLaren Cancer Institute-Macomb
-
Niles, Michigan, Forenede Stater, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Novi, Michigan, Forenede Stater, 48377
- Henry Ford Medical Center-Columbus
-
Petoskey, Michigan, Forenede Stater, 49770
- McLaren Cancer Institute-Northern Michigan
-
Port Huron, Michigan, Forenede Stater, 48060
- McLaren-Port Huron
-
Saginaw, Michigan, Forenede Stater, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Forenede Stater, 48601
- MyMichigan Medical Center Saginaw
-
Saint Joseph, Michigan, Forenede Stater, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Forenede Stater, 49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Shelby, Michigan, Forenede Stater, 48315
- Henry Ford Macomb Health Center - Shelby Township
-
Tawas City, Michigan, Forenede Stater, 48764
- MyMichigan Medical Center Tawas
-
West Bloomfield, Michigan, Forenede Stater, 48322
- Henry Ford West Bloomfield Hospital
-
West Branch, Michigan, Forenede Stater, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Wyoming, Michigan, Forenede Stater, 49519
- University of Michigan Health - West
-
Ypsilanti, Michigan, Forenede Stater, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Bemidji, Minnesota, Forenede Stater, 56601
- Sanford Joe Lueken Cancer Center
-
Brainerd, Minnesota, Forenede Stater, 56401
- Essentia Health Saint Joseph's Medical Center
-
Deer River, Minnesota, Forenede Stater, 56636
- Essentia Health - Deer River Clinic
-
Duluth, Minnesota, Forenede Stater, 55805
- Essentia Health Cancer Center
-
Duluth, Minnesota, Forenede Stater, 55805
- Essentia Health Saint Mary's Medical Center
-
Duluth, Minnesota, Forenede Stater, 55805
- Miller-Dwan Hospital
-
Hibbing, Minnesota, Forenede Stater, 55746
- Essentia Health Hibbing Clinic
-
Saint Cloud, Minnesota, Forenede Stater, 56303
- Coborn Cancer Center at Saint Cloud Hospital
-
Sandstone, Minnesota, Forenede Stater, 55072
- Essentia Health Sandstone
-
Virginia, Minnesota, Forenede Stater, 55792
- Essentia Health Virginia Clinic
-
-
Missouri
-
Cape Girardeau, Missouri, Forenede Stater, 63703
- Saint Francis Medical Center
-
City of Saint Peters, Missouri, Forenede Stater, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Forenede Stater, 63141
- Siteman Cancer Center at West County Hospital
-
Farmington, Missouri, Forenede Stater, 63640
- Parkland Health Center - Farmington
-
Joplin, Missouri, Forenede Stater, 64804
- Freeman Health System
-
Kansas City, Missouri, Forenede Stater, 64154
- University of Kansas Cancer Center - North
-
Lee's Summit, Missouri, Forenede Stater, 64064
- University of Kansas Cancer Center - Lee's Summit
-
North Kansas City, Missouri, Forenede Stater, 64116
- University of Kansas Cancer Center at North Kansas City Hospital
-
Rolla, Missouri, Forenede Stater, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Forenede Stater, 65401
- Phelps Health Delbert Day Cancer Institute
-
Springfield, Missouri, Forenede Stater, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Forenede Stater, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Forenede Stater, 63129
- Siteman Cancer Center-South County
-
-
Montana
-
Bozeman, Montana, Forenede Stater, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Forenede Stater, 59405
- Benefis Sletten Cancer Institute
-
-
Nebraska
-
Kearney, Nebraska, Forenede Stater, 68847
- CHI Health Good Samaritan
-
Omaha, Nebraska, Forenede Stater, 68198
- University of Nebraska Medical Center
-
-
Nevada
-
Reno, Nevada, Forenede Stater, 89502
- Renown Regional Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Forenede Stater, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
New Brunswick, New Jersey, Forenede Stater, 08903
- Rutgers Cancer Institute of New Jersey
-
Toms River, New Jersey, Forenede Stater, 08755
- Community Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87109
- New Mexico Oncology Hematology Consultants
-
Albuquerque, New Mexico, Forenede Stater, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Canandaigua, New York, Forenede Stater, 14424
- Sands Cancer Center
-
Dansville, New York, Forenede Stater, 14437
- Noyes Memorial Hospital/Myers Cancer Center
-
Oswego, New York, Forenede Stater, 13126
- Upstate Cancer Center at Oswego
-
Rochester, New York, Forenede Stater, 14642
- University of Rochester
-
Rochester, New York, Forenede Stater, 14620
- Highland Hospital
-
Stony Brook, New York, Forenede Stater, 11794
- Stony Brook University Medical Center
-
Syracuse, New York, Forenede Stater, 13210
- State University of New York Upstate Medical University
-
Syracuse, New York, Forenede Stater, 13215
- SUNY Upstate Medical Center-Community Campus
-
Verona, New York, Forenede Stater, 13478
- Upstate Cancer Center at Verona
-
Webster, New York, Forenede Stater, 14580
- Wilmot Cancer Institute at Webster
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, Forenede Stater, 28204
- Novant Health Presbyterian Medical Center
-
Charlotte, North Carolina, Forenede Stater, 28210
- Atrium Health Pineville/LCI-Pineville
-
Charlotte, North Carolina, Forenede Stater, 28262
- Atrium Health University City/LCI-University
-
Charlotte, North Carolina, Forenede Stater, 28277
- Levine Cancer Institute-Ballantyne
-
Clemmons, North Carolina, Forenede Stater, 27012
- Wake Forest University at Clemmons
-
Concord, North Carolina, Forenede Stater, 28025
- Atrium Health Cabarrus/LCI-Concord
-
Gastonia, North Carolina, Forenede Stater, 28054
- CaroMont Regional Medical Center
-
Greenville, North Carolina, Forenede Stater, 27834
- East Carolina University
-
Huntersville, North Carolina, Forenede Stater, 28078
- Novant Health Cancer Institute - Huntersville
-
Huntersville, North Carolina, Forenede Stater, 28078
- Novant Health Presbyterian Medical Center Huntersville
-
Kernersville, North Carolina, Forenede Stater, 27284
- Novant Health Cancer Institute - Kernersville
-
Matthews, North Carolina, Forenede Stater, 28105
- Novant Health Cancer Institute - Matthews
-
Monroe, North Carolina, Forenede Stater, 28112
- Atrium Health Union/LCI-Union
-
Mooresville, North Carolina, Forenede Stater, 28117
- Novant Health Cancer Institute - Mooresville
-
Mount Airy, North Carolina, Forenede Stater, 27030
- Novant Health Cancer Institute - Mount Airy
-
North Wilkesboro, North Carolina, Forenede Stater, 28659
- Novant Health Cancer Institute - Wilkesboro
-
Pinehurst, North Carolina, Forenede Stater, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Salisbury, North Carolina, Forenede Stater, 28144
- Novant Health Cancer Institute - Rowan
-
Statesville, North Carolina, Forenede Stater, 28625
- Novant Health Cancer Institute - Statesville
-
Statesville, North Carolina, Forenede Stater, 28677
- Wake Forest Baptist Health - Hematology Oncology - Statesville
-
Supply, North Carolina, Forenede Stater, 28462
- Novant Cancer Institute Radiation Oncology - Supply
-
Thomasville, North Carolina, Forenede Stater, 27360
- Novant Health Cancer Institute - Thomasville
-
Wilkesboro, North Carolina, Forenede Stater, 28659
- Wake Forest Baptist Health - Wilkes Medical Center
-
Wilmington, North Carolina, Forenede Stater, 28401
- Novant Health New Hanover Regional Medical Center
-
Wilmington, North Carolina, Forenede Stater, 28401
- Novant Health Cancer Institute Radiation Oncology - Wilmington
-
Winston-Salem, North Carolina, Forenede Stater, 27157
- Wake Forest University Health Sciences
-
Winston-Salem, North Carolina, Forenede Stater, 27103
- Novant Health Forsyth Medical Center
-
-
North Dakota
-
Bismarck, North Dakota, Forenede Stater, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Forenede Stater, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Forenede Stater, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Forenede Stater, 44304
- Summa Health System - Akron Campus
-
Avon, Ohio, Forenede Stater, 44011
- UH Seidman Cancer Center at UH Avon Health Center
-
Barberton, Ohio, Forenede Stater, 44203
- Summa Health System - Barberton Campus
-
Chardon, Ohio, Forenede Stater, 44024
- Geauga Hospital
-
Cincinnati, Ohio, Forenede Stater, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cleveland, Ohio, Forenede Stater, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Forenede Stater, 44109
- MetroHealth Medical Center
-
Cleveland, Ohio, Forenede Stater, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Forenede Stater, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, Forenede Stater, 43210
- Ohio State University Comprehensive Cancer Center
-
Mansfield, Ohio, Forenede Stater, 44906
- Cleveland Clinic Cancer Center Mansfield
-
Mayfield Heights, Ohio, Forenede Stater, 44124
- Hillcrest Hospital Cancer Center
-
Medina, Ohio, Forenede Stater, 44256
- Summa Health Medina Medical Center
-
Mentor, Ohio, Forenede Stater, 44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Middleburg Heights, Ohio, Forenede Stater, 44130
- UH Seidman Cancer Center at Southwest General Hospital
-
Parma, Ohio, Forenede Stater, 44129
- University Hospitals Parma Medical Center
-
Perrysburg, Ohio, Forenede Stater, 43551
- Mercy Health - Perrysburg Hospital
-
Ravenna, Ohio, Forenede Stater, 44266
- University Hospitals Portage Medical Center
-
Sandusky, Ohio, Forenede Stater, 44870
- North Coast Cancer Care
-
Strongsville, Ohio, Forenede Stater, 44136
- Cleveland Clinic Cancer Center Strongsville
-
Sylvania, Ohio, Forenede Stater, 43560
- ProMedica Flower Hospital
-
Toledo, Ohio, Forenede Stater, 43623
- Mercy Health - Saint Anne Hospital
-
Toledo, Ohio, Forenede Stater, 43608
- Mercy Health - Saint Vincent Hospital
-
Toledo, Ohio, Forenede Stater, 43623
- Mercy Health Sylvania Radiation Oncology Center
-
West Chester, Ohio, Forenede Stater, 45069
- University of Cincinnati Cancer Center-West Chester
-
Westlake, Ohio, Forenede Stater, 44145
- UH Seidman Cancer Center at Saint John Medical Center
-
Westlake, Ohio, Forenede Stater, 44145
- UHHS-Westlake Medical Center
-
Wooster, Ohio, Forenede Stater, 44691
- Cleveland Clinic Wooster Family Health and Surgery Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Clackamas, Oregon, Forenede Stater, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Forenede Stater, 97015
- Providence Cancer Institute Clackamas Clinic
-
Newberg, Oregon, Forenede Stater, 97132
- Providence Newberg Medical Center
-
Oregon City, Oregon, Forenede Stater, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Forenede Stater, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Forenede Stater, 97225
- Providence Saint Vincent Medical Center
-
Portland, Oregon, Forenede Stater, 97227
- Kaiser Permanente Northwest
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forenede Stater, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Altoona, Pennsylvania, Forenede Stater, 16601
- UPMC Altoona
-
Beaver, Pennsylvania, Forenede Stater, 15009
- UPMC-Heritage Valley Health System Beaver
-
Carlisle, Pennsylvania, Forenede Stater, 17015
- Carlisle Regional Cancer Center
-
Chadds Ford, Pennsylvania, Forenede Stater, 19317
- Christiana Care Health System-Concord Health Center
-
Chambersburg, Pennsylvania, Forenede Stater, 17201
- Chambersburg Hospital
-
Danville, Pennsylvania, Forenede Stater, 17822
- Geisinger Medical Center
-
East Norriton, Pennsylvania, Forenede Stater, 19401
- Fox Chase Cancer Center - East Norriton Hospital Outpatient Center
-
Ephrata, Pennsylvania, Forenede Stater, 17522
- Ephrata Cancer Center
-
Erie, Pennsylvania, Forenede Stater, 16505
- UPMC Hillman Cancer Center Erie
-
Farrell, Pennsylvania, Forenede Stater, 16121
- UPMC Cancer Center at UPMC Horizon
-
Furlong, Pennsylvania, Forenede Stater, 18925
- Fox Chase Cancer Center Buckingham
-
Gettysburg, Pennsylvania, Forenede Stater, 17325
- Adams Cancer Center
-
Greensburg, Pennsylvania, Forenede Stater, 15601
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Harrisburg, Pennsylvania, Forenede Stater, 17109
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Hershey, Pennsylvania, Forenede Stater, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Johnstown, Pennsylvania, Forenede Stater, 15901
- UPMC-Johnstown/John P. Murtha Regional Cancer Center
-
Lewisburg, Pennsylvania, Forenede Stater, 17837
- Geisinger Medical Oncology-Lewisburg
-
Lewistown, Pennsylvania, Forenede Stater, 17044
- Lewistown Hospital
-
McKeesport, Pennsylvania, Forenede Stater, 15132
- UPMC Cancer Center at UPMC McKeesport
-
Mechanicsburg, Pennsylvania, Forenede Stater, 17050
- UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
-
Monroeville, Pennsylvania, Forenede Stater, 15146
- Forbes Hospital
-
Monroeville, Pennsylvania, Forenede Stater, 15146
- UPMC Cancer Center - Monroeville
-
Moon Township, Pennsylvania, Forenede Stater, 15108
- UPMC Hillman Cancer Center in Coraopolis
-
Philadelphia, Pennsylvania, Forenede Stater, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, Forenede Stater, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Forenede Stater, 19114
- Jefferson Torresdale Hospital
-
Philadelphia, Pennsylvania, Forenede Stater, 19140
- Temple University Hospital
-
Pittsburgh, Pennsylvania, Forenede Stater, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Forenede Stater, 15213
- UPMC-Magee Womens Hospital
-
Pittsburgh, Pennsylvania, Forenede Stater, 15232
- UPMC-Shadyside Hospital
-
Pittsburgh, Pennsylvania, Forenede Stater, 15215
- UPMC-Saint Margaret
-
Pittsburgh, Pennsylvania, Forenede Stater, 15237
- UPMC-Passavant Hospital
-
Pittsburgh, Pennsylvania, Forenede Stater, 15243
- UPMC-Saint Clair Hospital Cancer Center
-
Pottsville, Pennsylvania, Forenede Stater, 17901
- Geisinger Cancer Services-Pottsville
-
Seneca, Pennsylvania, Forenede Stater, 16346
- UPMC Cancer Center at UPMC Northwest
-
Uniontown, Pennsylvania, Forenede Stater, 15401
- UPMC Uniontown Hospital Radiation Oncology
-
Washington, Pennsylvania, Forenede Stater, 15301
- UPMC Washington Hospital Radiation Oncology
-
West Reading, Pennsylvania, Forenede Stater, 19611
- Reading Hospital
-
Wexford, Pennsylvania, Forenede Stater, 15090
- Wexford Health and Wellness Pavilion
-
Wilkes-Barre, Pennsylvania, Forenede Stater, 18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
Williamsport, Pennsylvania, Forenede Stater, 17754
- Divine Providence Hospital
-
Willow Grove, Pennsylvania, Forenede Stater, 19090
- Asplundh Cancer Pavilion
-
York, Pennsylvania, Forenede Stater, 17403
- WellSpan Health-York Cancer Center
-
York, Pennsylvania, Forenede Stater, 17403
- WellSpan Health-York Hospital
-
York, Pennsylvania, Forenede Stater, 17408
- UPMC Memorial
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29425
- Medical University of South Carolina
-
Gaffney, South Carolina, Forenede Stater, 29341
- Gibbs Cancer Center-Gaffney
-
Georgetown, South Carolina, Forenede Stater, 29440
- Tidelands Georgetown Memorial Hospital
-
Greenville, South Carolina, Forenede Stater, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Forenede Stater, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Forenede Stater, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Forenede Stater, 29601
- Saint Francis Hospital
-
Greer, South Carolina, Forenede Stater, 29650
- Prisma Health Cancer Institute - Greer
-
Greer, South Carolina, Forenede Stater, 29651
- Gibbs Cancer Center-Pelham
-
Rock Hill, South Carolina, Forenede Stater, 29732
- Levine Cancer Institute-Rock Hill
-
Rock Hill, South Carolina, Forenede Stater, 29730
- Rock Hill Radiation Therapy Center
-
Seneca, South Carolina, Forenede Stater, 29672
- Prisma Health Cancer Institute - Seneca
-
Spartanburg, South Carolina, Forenede Stater, 29303
- Spartanburg Medical Center
-
Union, South Carolina, Forenede Stater, 29379
- SMC Center for Hematology Oncology Union
-
-
South Dakota
-
Sioux Falls, South Dakota, Forenede Stater, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Forenede Stater, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Forenede Stater, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Germantown, Tennessee, Forenede Stater, 38138
- The West Clinic - Wolf River
-
Knoxville, Tennessee, Forenede Stater, 37920
- University of Tennessee - Knoxville
-
Nashville, Tennessee, Forenede Stater, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Amarillo, Texas, Forenede Stater, 79106
- The Don and Sybil Harrington Cancer Center
-
-
Utah
-
American Fork, Utah, Forenede Stater, 84003
- American Fork Hospital / Huntsman Intermountain Cancer Center
-
Farmington, Utah, Forenede Stater, 84025
- Farmington Health Center
-
Logan, Utah, Forenede Stater, 84321
- Logan Regional Hospital
-
Murray, Utah, Forenede Stater, 84107
- Intermountain Medical Center
-
Ogden, Utah, Forenede Stater, 84403
- McKay-Dee Hospital Center
-
Provo, Utah, Forenede Stater, 84604
- Utah Valley Regional Medical Center
-
Riverton, Utah, Forenede Stater, 84065
- Riverton Hospital
-
Salt Lake City, Utah, Forenede Stater, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, Forenede Stater, 84106
- Utah Cancer Specialists-Salt Lake City
-
Salt Lake City, Utah, Forenede Stater, 84143
- LDS Hospital
-
St. George, Utah, Forenede Stater, 84770
- Saint George Regional Medical Center
-
-
Vermont
-
Saint Johnsbury, Vermont, Forenede Stater, 05819
- Dartmouth Cancer Center - North
-
-
Virginia
-
Fairfax, Virginia, Forenede Stater, 22031
- Inova Schar Cancer Institute
-
Fairfax, Virginia, Forenede Stater, 22033
- Inova Fair Oaks Hospital
-
Portsmouth, Virginia, Forenede Stater, 23708-2197
- Naval Medical Center - Portsmouth
-
Richmond, Virginia, Forenede Stater, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Forenede Stater, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Renton, Washington, Forenede Stater, 98055
- Valley Medical Center
-
Seattle, Washington, Forenede Stater, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Forenede Stater, 98122
- Swedish Medical Center-First Hill
-
Walla Walla, Washington, Forenede Stater, 99362
- Providence Saint Mary Regional Cancer Center
-
-
Wisconsin
-
Antigo, Wisconsin, Forenede Stater, 54409
- Aspirus Cancer Care-Antigo-Volm Cancer Center
-
Appleton, Wisconsin, Forenede Stater, 54915
- Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton
-
Ashland, Wisconsin, Forenede Stater, 54806
- Duluth Clinic Ashland
-
Ashland, Wisconsin, Forenede Stater, 54806
- Northwest Wisconsin Cancer Center
-
Brookfield, Wisconsin, Forenede Stater, 53045
- Ascension Southeast Wisconsin Hospital-Elmbrook Campus-Brookfield
-
Burlington, Wisconsin, Forenede Stater, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Chilton, Wisconsin, Forenede Stater, 53014
- Ascension Calumet Hospital-Chilton
-
Eau Claire, Wisconsin, Forenede Stater, 54701
- HSHS Sacred Heart Hospital
-
Franklin, Wisconsin, Forenede Stater, 53132
- Ascension Southeast Wisconsin Hospital - Franklin
-
Franklin, Wisconsin, Forenede Stater, 53132
- Reiman Cancer Center-Ascension Wisconsin Health Center-Rawson
-
Germantown, Wisconsin, Forenede Stater, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Forenede Stater, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Forenede Stater, 54311
- Aurora BayCare Medical Center
-
Green Bay, Wisconsin, Forenede Stater, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Green Bay, Wisconsin, Forenede Stater, 54303
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
Hayward, Wisconsin, Forenede Stater, 54843
- Essentia Health-Hayward Clinic
-
Johnson Creek, Wisconsin, Forenede Stater, 53038
- University of Wisconsin Carbone Cancer Center - Johnson Creek
-
Kenosha, Wisconsin, Forenede Stater, 53142
- Aurora Cancer Care-Kenosha South
-
La Crosse, Wisconsin, Forenede Stater, 54601
- Gundersen Lutheran Medical Center
-
Madison, Wisconsin, Forenede Stater, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marinette, Wisconsin, Forenede Stater, 54143
- Aurora Bay Area Medical Group-Marinette
-
Menomonee Falls, Wisconsin, Forenede Stater, 53051
- Froedtert Menomonee Falls Hospital
-
Mequon, Wisconsin, Forenede Stater, 53097
- Ascension Columbia Saint Mary's Hospital-Ozaukee Campus-Mequon
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Medical College of Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Forenede Stater, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Forenede Stater, 53233
- Aurora Sinai Medical Center
-
Milwaukee, Wisconsin, Forenede Stater, 53210
- Ascension Southeast Wisconsin Hospital-Saint Joseph-Milwaukee
-
Milwaukee, Wisconsin, Forenede Stater, 53211
- Ascension Columbia Saint Mary's Hospital-Milwaukee Campus
-
Milwaukee, Wisconsin, Forenede Stater, 53215
- Ascension Saint Francis Hospital-Milwaukee
-
Oshkosh, Wisconsin, Forenede Stater, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Oshkosh, Wisconsin, Forenede Stater, 54904
- Ascension Northeast Wisconsin-Mercy Hospital-Oshkosh
-
Racine, Wisconsin, Forenede Stater, 53406
- Aurora Cancer Care-Racine
-
Racine, Wisconsin, Forenede Stater, 53405
- Ascension All Saints Hospital-Spring Street-Racine
-
Rhinelander, Wisconsin, Forenede Stater, 54501
- Aspirus Cancer Care-Rhinelander-James Beck Cancer Center
-
Sheboygan, Wisconsin, Forenede Stater, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Spooner, Wisconsin, Forenede Stater, 54801
- Essentia Health-Spooner Clinic
-
Stevens Point, Wisconsin, Forenede Stater, 54481
- Aspirus Cancer Care - Stevens Point
-
Summit, Wisconsin, Forenede Stater, 53066
- Aurora Medical Center in Summit
-
Superior, Wisconsin, Forenede Stater, 54880
- Essentia Health Saint Mary's Hospital - Superior
-
Two Rivers, Wisconsin, Forenede Stater, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Wausau, Wisconsin, Forenede Stater, 54401
- Aspirus Cancer Care-Wausau
-
Wauwatosa, Wisconsin, Forenede Stater, 53226
- Aurora Cancer Care-Milwaukee West
-
Wauwatosa, Wisconsin, Forenede Stater, 53226
- Ascension Southeast Wisconsin Hospital-Mayfair Road-Wauwatosa
-
West Allis, Wisconsin, Forenede Stater, 53227
- Aurora West Allis Medical Center
-
West Bend, Wisconsin, Forenede Stater, 53095
- Froedtert West Bend Hospital/Kraemer Cancer Center
-
Wisconsin Rapids, Wisconsin, Forenede Stater, 54494
- Aspirus Cancer Care - Wisconsin Rapids
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma (including the histological variants papillary squamous cell carcinoma and basaloid squamous cell carcinoma but not neuroendocrine phenotype) of the oropharynx (tonsil, base of tongue, soft palate, or oropharyngeal walls); cytologic diagnosis from a cervical lymph node is sufficient in the presence of clinical evidence of a primary tumor in the oropharynx. Clinical evidence should be documented, may consist of palpation, imaging, or endoscopic evaluation, and should be sufficient to estimate the size of the primary (for T stage)
-
Patients must have clinically or radiographically evident measurable disease at the primary site or at nodal stations. Simple tonsillectomy or local excision of the primary without removal of nodal disease is permitted, as is excision removing gross nodal disease but with intact primary site. Limited neck dissections retrieving =< 4 nodes are permitted and considered as non-therapeutic nodal excisions
-
P16-positive based on local site immunohistochemical tissue staining (defined as greater than 70% strong diffuse nuclear or nuclear and cytoplasmic staining of tumor cells). Fine needle aspiration (FNA) biopsy specimens may be used as the sole diagnostic tissue. Centers are encouraged to contact the pathology chair for clarification
- Note: Institutions must screen patients, whose tumors must be p16-positive by immunohistochemistry (IHC) in order to be eligible for the trial using a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. A rigorous laboratory accreditation process similar to the United States (U.S.) CLIA certification, such as the provincial accreditation status offered by the Ontario Laboratory Accreditation (OLA) Program in Canada, the College of American Pathologists (CAP), or an equivalent accreditation in other countries, is acceptable. The p16-positive results must be reported on the pathology report being submitted
- Note: If p16 result is equivocal, positive HPV deoxyribonucleic acid (DNA) test of tumor specimen is acceptable and fulfills the eligibility criteria
-
Clinical stage T1-2, N1, M0 (American Joint Committee on Cancer [AJCC], 8th edition [ed.]) or T3, N0-N1, M0 (AJCC, 8th ed.) including no distant metastases based on the following diagnostic workup:
-
General history and physical examination within 56 days prior to registration;
-
Exam with laryngopharyngoscopy (mirror or in office direct procedure acceptable) within 70 days prior to registration;
-
One of the following imaging studies is required within 56 days prior to registration:
- FDG-PET/CT of the neck and chest (with or without contrast); FDG-PET/CT scan is strongly preferred and highly recommended to be used for eligibility OR
- Chest CT (with or without contrast)
-
One of the following imaging studies is required within 28 days prior to registration:
- A diagnostic CT scan of neck (with contrast and of diagnostic quality) OR
- An magnetic resonance imaging (MRI) of the neck (with contrast and of diagnostic quality)
- Note: A diagnostic quality CT or MRI with contrast or FDG-PET/CT scan of neck performed for the purposes of radiation planning may serve as both staging and planning tools
-
-
Patients must provide their personal smoking history prior to registration. The lifetime cumulative history cannot exceed 10 pack-years. The following formula is used to calculate the pack-years during the periods of smoking in the patient's life; the cumulative total of the number of pack-years during each period of active smoking is the lifetime cumulative history
- Number of pack-years = [Frequency of smoking (number of cigarettes per day) x duration of cigarette smoking (years)] / 20
- Note: Twenty cigarettes is considered equivalent to one pack. The effect of non-cigarette tobacco products on the survival of patients with p16-positive oropharyngeal cancers is undefined. While there are reportedly increased risks of head and neck cancer associated with sustained heavy cigar and pipe use (Wyss 2013), such sustained use of non-cigarette products is unusual and does not appear to convey added risk with synchronous cigarette smoking. Cigar and pipe tobacco consumption is therefore not included in calculating the lifetime pack-years. Marijuana consumption is likewise not considered in this calculation. There is no clear scientific evidence regarding the role of chewing tobacco-containing products in this disease, although this is possibly more concerning given the proximity of the oral cavity and oropharynx. In any case, investigators are discouraged from enrolling patients with a history of very sustained use (such as several years or more) of non-cigarette tobacco products alone
-
Zubrod performance status of 0-1 within 14 days prior to registration
-
Age >= 18
-
Absolute neutrophil count >= 1,500/mcL (within 14 days prior to registration)
-
Platelets >= 100,000/mcL (within 14 days prior to registration)
-
Hemoglobin >= 8.0 g/dL (within 14 days prior to registration) (Note: use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dL is acceptable)
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (within 14 days prior to registration)
-
Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase [SGOT]) or alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) =< 3.0 x institutional ULN (within 14 days prior to registration)
-
Serum creatinine =< 1.5 x ULN OR creatinine clearance (CrCl) >= 50 mL/min (if using the Cockcroft-Gault formula) (within 14 days prior to registration)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Note: Known positive test for hepatitis B virus surface antigen (HBV sAg) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy. Patients who are immune to hepatitis B (anti-hepatitis B surface antibody positive) are eligible (e.g. patients immunized against hepatitis B)
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment for the hepatitis, they are eligible if they have an undetectable HCV viral load.
- Note: Known positive test for hepatitis C virus ribonucleic acid (HCV RNA) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy
-
For women of childbearing potential (WOCBP), negative serum or urine pregnancy test within 24 hours prior to registration
- Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL
-
Women of childbearing potential (WOCBP) and men who are sexually active with WOCBP must be willing to use an adequate method of contraception during and after treatment
-
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
-
Only English, Spanish, or French speaking patients are eligible to participate as these are the only languages for which the mandatory dysphagia-related patient reported instrument (MDADI) is available
Exclusion Criteria:
-
Clinical stages T0; T4; T1-2, N0; or any N2 (AJCC, 8th ed)
-
Recurrent disease
-
Definitive clinical or radiologic evidence of metastatic disease or adenopathy below the clavicles
-
Cancers considered to be from an oral cavity site (oral tongue, floor mouth, alveolar ridge, buccal or lip), or the nasopharynx, hypopharynx, or larynx, even if p16-positive, or histologies of adenosquamous, verrucous, or spindle cell carcinomas
-
Carcinoma of the neck of unknown primary site origin (T0 is ineligible, even if p16-positive)
-
Radiographically matted nodes, defined as 3 abutting nodes with loss of the intervening fat plane
-
Supraclavicular nodes, defined as nodes centered below the level of the cricoid cartilage
-
Gross total excision of both primary and nodal disease; this includes tonsillectomy, local excision of primary site, and nodal excision that removes all clinically and radiographically evident disease. In other words, to participate in this protocol, the patient must have clinically or radiographically evident gross disease for which disease response can be assessed
-
Patients with simultaneous primary cancers or separate bilateral primary tumor sites are excluded with the exception of patients with bilateral tonsil cancers
-
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 years) (of note, the exclusion applies only for invasive cancers such that carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
-
Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable
-
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
-
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
-
History of severe hypersensitivity reaction to any monoclonal antibody.
-
Severe, active co-morbidity defined as follows:
- Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
- Transmural myocardial infarction within the last 6 months
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
- Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration
- Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
- Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition with immune compromise greater than that noted; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. Protocol-specific requirements may also exclude immuno-compromised patients
- Condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of registration. Inhaled or topical steroids and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
- Patients with active autoimmune disease requiring systemic treatment (i.e. disease modifying agents, corticosteroids, or immunosuppressive drugs) should be excluded. These include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), rheumatoid arthritis, connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease
- Note: Patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event)
-
Patients who are pregnant, nursing, or expecting to conceive or father children
-
Prior allergic reaction to cisplatin
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Arm I (Standard RT + cisplatin)
Patients undergo standard dose RT as 70 Gy IMRT or IGRT over 6 fractions per week and receive 100 mg/m^2/day cisplatin IV over 30-60 minutes on days 1 and 22. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive FDG and undergo PET/CT or CT during screening and during follow up, and undergo MRI during follow up. Patients may also undergo tissue biopsy and blood sample collection throughout the study. |
Ancillary studies
Andre navne:
Given IV
Andre navne:
Undergo blood sample collection
Andre navne:
Undergo CT
Andre navne:
Undergo MRI
Andre navne:
Ancillary studies Undergo PET
Andre navne:
Undergo IMRT
Andre navne:
Receive FDG
Andre navne:
Undergo tissue biopsy
Andre navne:
Undergo IGRT
Andre navne:
|
|
Eksperimentel: Arm II (Reduced RT + cisplatin)
Patients undergo reduced dose RT as 60 Gy IMRT or IGRT QD over 5 fractions per week and receive 100 mg/m^2/day cisplatin IV over 30-60 minutes on days 1 and 22. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive FDG and undergo PET/CT or CT during screening and during follow up, and undergo MRI during follow up. Patients may also undergo tissue biopsy and blood sample collection throughout the study. |
Ancillary studies
Andre navne:
Given IV
Andre navne:
Undergo blood sample collection
Andre navne:
Undergo CT
Andre navne:
Undergo MRI
Andre navne:
Ancillary studies Undergo PET
Andre navne:
Undergo IMRT
Andre navne:
Receive FDG
Andre navne:
Undergo tissue biopsy
Andre navne:
Undergo IGRT
Andre navne:
|
|
Eksperimentel: Arm III (Reduced RT + nivolumab)
Beginning 1 week prior to radiation, patients receive 240 mg fixed dose nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks (14 days) for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo reduced dose RT as 60 Gy IMRT or IGRT over 6 fractions per week for 5 weeks in the absence of disease progression or unacceptable toxicity. Patients receive FDG and undergo PET/CT or CT during screening and during follow up, and undergo MRI during follow up. Patients may also undergo tissue biopsy and blood sample collection throughout the study. |
Ancillary studies
Andre navne:
Undergo blood sample collection
Andre navne:
Undergo CT
Andre navne:
Ancillary studies Undergo PET
Andre navne:
Given IV
Andre navne:
Undergo IMRT
Andre navne:
Receive FDG
Andre navne:
Undergo tissue biopsy
Andre navne:
Undergo IGRT
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free Survival (PFS) (Phase II) (Percentage of Participants Alive Without Progression)
Tidsramme: From randomization to first progression or last follow-up. Maximum follow-up at the time of analysis was 4.6 years. The 1- and 2-year estimates are reported.
|
Progression is defined as local-regional progression or recurrence, distant metastasis, death due to any reason, salvage surgery of primary with tumor present/unknown, salvage neck dissection with tumor present/unknown, > 20 weeks from end of radiation therapy. Progression-free survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis. The primary phase IIR endpoint is tested using a confidence interval (CI) approach with each experimental arm compared to the standard arm (Arm 1). |
From randomization to first progression or last follow-up. Maximum follow-up at the time of analysis was 4.6 years. The 1- and 2-year estimates are reported.
|
|
Progression-free Survival (Phase III) (Percentage of Participants Alive Without Progression)
Tidsramme: From randomization to first progression or last follow-up. Maximum follow-up was 4.6 years.
|
Progression is defined as local-regional progression or recurrence, distant metastasis, death due to any reason, salvage surgery of primary with tumor present/unknown, salvage neck dissection with tumor present/unknown, > 20 weeks from end of radiation therapy. Progression-free survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis. |
From randomization to first progression or last follow-up. Maximum follow-up was 4.6 years.
|
|
MD Anderson Dysphagia Inventory (MDADI) Global Quality of Life (QOL) Score
Tidsramme: Baseline to two years
|
The M. D. Anderson Dysphagia Inventory (MDADI) assesses how patients view their swallowing ability as a result of treatment and how this affects their QOL. It consists of a global quality of life question and a functional, emotional, and physical subscale. The global QOL question ranges from 1 to 5 and multiplied by 20 to obtain a score with a range of 0 to 100. Higher scores indicate better functioning. |
Baseline to two years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Locoregional Failure (Percentage of Participants With Locoregional Failure)
Tidsramme: From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Maximum follow-up at the time of analysis was 4.6 years. The 1- and 2-year estimates are reported.
|
Locoregional failure is defined as local-regional progression or recurrence, death due to study cancer or unknown causes, salvage neck dissection with tumor present/unknown. Locoregional failure rates are estimated the cumulative incidence method, treating distant metastasis and death due to any reason other than study cancer or unknown as competing risks, and otherwise censoring participants alive at time of analysis. Each experimental arm is compared to the standard arm (Arm I). |
From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Maximum follow-up at the time of analysis was 4.6 years. The 1- and 2-year estimates are reported.
|
|
Distant Failure (Percentage of Participants With Distant Failure)
Tidsramme: From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Maximum follow-up at the time of analysis was 4.6 years. The 1- and 2-year estimates are reported.
|
Distant failure is defined as the occurrence of distant metastasis. Distant failure rates are estimated the cumulative incidence method, treating local-regional progression or recurrence, death due to any reason, salvage neck dissection with tumor present/unknown as competing risks, and otherwise censoring participants alive at time of analysis. Each experimental arm is compared to the standard arm (Arm I). |
From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Maximum follow-up at the time of analysis was 4.6 years. The 1- and 2-year estimates are reported.
|
|
Overall Survival (Percentage of Participants Alive)
Tidsramme: From randomization to death from any cause or last follow-up. Maximum follow-up at the time of analysis was 4.6 years. The 1- and 2-year estimates are reported.
|
Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis. |
From randomization to death from any cause or last follow-up. Maximum follow-up at the time of analysis was 4.6 years. The 1- and 2-year estimates are reported.
|
|
Number of Participants by Highest Grade Adverse Event Reported
Tidsramme: From randomization to last known follow-up. Maximum follow-up at the time of analysis was 4.6 years.
|
Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. |
From randomization to last known follow-up. Maximum follow-up at the time of analysis was 4.6 years.
|
|
Hearing
Tidsramme: Baseline up to 24 months from end of radiation therapy (RT)
|
Measured as Hearing Handicap Inventory for Adults-Screening (HHIA-S). |
Baseline up to 24 months from end of radiation therapy (RT)
|
|
Quality of Life
Tidsramme: Baseline up to 24 months from end of RT
|
Measured by the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire (QLQ)30. |
Baseline up to 24 months from end of RT
|
|
Fludeoxyglucose F-18 (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) Locoregional Control
Tidsramme: Up to 6 years
|
Will be associated with PFS. |
Up to 6 years
|
|
Negative Predictive Value of Post-RT FDG-PET/CT for Locoregional Control
Tidsramme: At 1 and 2 years
|
The negative predictive value of FDG-PET/CT for locoregional control will be estimated using binomial proportions and confidence intervals based on normal approximation. |
At 1 and 2 years
|
|
Negative Predictive Value of Post-RT FDG-PET/CT for PFS
Tidsramme: At 1 and 2 years
|
The negative predictive value of FDG-PET/CT PFS will be estimated using binomial proportions and confidence intervals based on normal approximation. |
At 1 and 2 years
|
|
Incidence of Adverse Events
Tidsramme: Up to 6 years
|
Measured using Patient-Reported Outcomes (PRO)-CTCAE. For each symptom, counts and frequencies will be provided for the worst score experienced by the patient by treatment arm. The proportion of patients with scores >= 1 and >= 3 will be compared between groups using a Chi-square test, or Fisher's exact test if cell frequencies are < 5, using a significance level of 0.05. Analysis of changes in patient reported outcomes over time will analyzed by fitting generalized estimating equations (GEE) models using a logit link (dichotomizing the symptom scores as 0 vs. > 1 and 0-2 vs. 3-4) with time of assessment, treatment arm, and treatment-by-time interaction terms in the model. |
Up to 6 years
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Quality of Life
Tidsramme: Baseline up to 24 months from end of RT
|
Measured by EuroQol-5 Dimensional- 5 Level (EQ-5D-5L). |
Baseline up to 24 months from end of RT
|
|
Swallowing Physiology
Tidsramme: Up to 6 years
|
Measured by a Modified Barium Swallow (MBS) test. The proportion of aspiration for each arm will be estimated assuming a binomial distribution and between arm comparison will be performed using a Fisher's exact test. |
Up to 6 years
|
|
Locoregional Control for Patients With Post-RT FDG-PET/CT
Tidsramme: At 12-14 weeks post-RT
|
Locoregional control rates will be compared between negative and positive/undetermined patients. Cox proportional hazards models will be used to determine whether there are differences between these two groups, while adjusting for treatment arm and other covariates (cause-specific Cox models for locoregional failure). |
At 12-14 weeks post-RT
|
|
PFS for Patients With Post-RT FDG-PET/CT
Tidsramme: At 12-14 weeks post-RT
|
PFS rates will be compared between negative and positive/undetermined patients. Cox proportional hazards models will be used to determine whether there are differences between these two groups, while adjusting for treatment arm and other covariates (cause-specific Cox models for locoregional failure). |
At 12-14 weeks post-RT
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Sue S Yom, NRG Oncology
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Stomatognatiske sygdomme
- Neoplasmer efter sted
- Neoplasmer
- Neoplasmer efter histologisk type
- Neoplasmer i hoved og hals
- Neoplasmer, kirtel og epitel
- Karcinom
- Neoplasmer, pladecelle
- Otorhinolaryngologiske sygdomme
- Pharyngeale neoplasmer
- Otorhinolaryngologiske neoplasmer
- Pharyngeale sygdomme
- Planocellulært karcinom i hoved og hals
- Karcinom, pladecelle
- Orofaryngeale neoplasmer
- Aminosyrer, peptider og proteiner
- Proteiner
- Undersøgelsesteknikker
- Terapeutik
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Kirurgiske procedurer, operative
- Cytologiske teknikker
- Cytodiagnose
- Kulhydrater
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Uorganiske kemikalier
- Klorforbindelser
- Nitrogenforbindelser
- Elementer
- Metaller
- Diagnostiske teknikker, kirurgisk
- Kemiteknikker, analytisk
- Spektrumanalyse
- Metaller, tung
- Platinforbindelser
- Strålebehandling
- Deoxyglucose
- Deoxy sukker
- Overgangselementer
- Strålebehandling, konform
- Strålebehandling, computerassisteret
- Nivolumab
- Fluorodeoxyglucose F18
- Cisplatin
- 1,2-diaminocyclohexanplatin II-citrat
- Biopsi
- Håndtering af eksemplar
- Magnetisk resonansspektroskopi
- Platinum
- Strålebehandling, intensitetsmoduleret
- Strålebehandling, billedstyret
Andre undersøgelses-id-numre
- NCI-2019-03015
- U10CA180868 (U.S. NIH-bevilling/kontrakt)
- NCI-2019-03015 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- NRG-HN005 (Anden identifikator: CTEP)
- NRG-HN005 (Anden identifikator: NRG Oncology)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .